To develop an all-injectable long-acting HIV therapy, Frontier Biotech has designed and developed a combination regimen of Albuvirtide (ABT) and 3BNC117, a recombinant fully human monoclonal antibody with broadly neutralizing effects to HIV-1 viruses.

3BNC117 is one of the most clinically advanced anti-HIV bNAbs in the world, which not only exhibits long-acting anti-HIV efficacy, but also has been clinically proven to elicit human immune response to curtail HIV-infected cells, resulting in delayed viral rebound (or preventing viral remission). 3BNC117 has also exhibited an excellent safety profile in both healthy and HIV-1-infected individuals. 3BNC117 specifically binds to the CD4 binding site (CD4bs) within HIV-1 envelope glycoprotein 120 (gp120), and its mechanism of action is complementary and potentially synergetic to that of Albuvirtide (ABT), therefore the combination regimen consisted of Albuvirtide (ABT) and 3BNC117 may lead to a significant paradigm shift of the HIV treatment and provides great potential in achieving maximal HIV viral suppression including multiple drug resistance viruses, as well as to be used for HIV prophylaxis application.

If you are interested in access to Frontier's investigational drugs, please find the expanded access policy here.

.